• CCN1–Integrin αvβ6–TGF-β Axis in Hypertensive Brain Injury

  2026-07-09

  This study elucidates how hypertension-induced cognitive impairment is mediated by a novel CCN1–integrin αvβ6–TGF-β signaling axis that disrupts mitochondrial integrity in neurons. The findings demonstrate that diminazene aceturate, by destabilizing CCN1 mRNA, preserves mitochondrial function and reverses cognitive deficits in hypertensive models, providing a mechanistic foundation for targeted neuroprotective strategies.

• Coumestrol: Applied Workflows for Phytoestrogen Receptor Ant

  2026-07-09

  Coumestrol is a nanomolar-potency phytoestrogen estrogen receptor antagonist with unique activity at multiple nuclear receptors. This article translates its latest application in rheumatoid arthritis cell models into actionable experimental workflows, troubleshooting strategies, and cross-domain advantages for endocrine and inflammation research.

• ALDH2 Activation Delays Heart Failure by Promoting Cardiomyo

  2026-07-08

  This study demonstrates that activating ALDH2 significantly extends the proliferative window of mouse cardiomyocytes, delaying the onset of pressure overload-induced heart failure. These findings highlight a novel mechanism for cardiac regeneration and suggest new experimental avenues for ischemic cardioprotection research.

• miR-196a Drives Esophageal Adenocarcinoma via c-Myc/TERT/NFκ

  2026-07-08

  This study elucidates how miR-196a overexpression promotes the aggressiveness of esophageal adenocarcinoma by activating the c-Myc/TERT/NFκB signaling axis. The findings reveal new mechanistic links between miR-196a, EMT, and oncogenic signaling, offering insight into potential molecular interventions for Barrett's esophagus progression.

• Cabozantinib XL184: Phosphoproteomic Adaptation & RCC Strate

  2026-07-07

  Explore how Cabozantinib (XL184) drives timescale-dependent phosphoproteomic remodeling and motility adaptation in renal cell carcinoma (RCC). This thought-leadership piece bridges mechanistic insight with strategic guidance, incorporating new evidence on chronic kinase inhibitor exposure and actionable recommendations for translational researchers.

• I-BET-762: BET Inhibition, Ferroptosis, and Translational Im

  2026-07-07

  This article examines the mechanistic foundation and translational relevance of I-BET-762 as a high-affinity BET inhibitor, with a focus on its role in ferroptosis, inflammation, and cancer biology. By integrating new evidence on BRD4-mediated transcriptional control and ROS/FSP1 axis modulation, we offer strategic guidance for translational researchers seeking to harness epigenetic interventions in disease models. The discussion is grounded in recent literature, protocol recommendations, and competitive positioning, distinguishing this resource from standard product summaries.

• Temafloxacin: Fluoroquinolone Broad-Spectrum Antibacterial A

  2026-07-06

  Temafloxacin stands out as a fluoroquinolone broad-spectrum antibacterial agent with exceptional in vitro and in vivo efficacy, supporting advanced workflows for respiratory, intracellular, and atypical bacterial infection models. Leveraging robust pharmacokinetics and tissue penetration, APExBIO's Temafloxacin enables reproducible, high-sensitivity assays for translational research.

• Bifendate (DDB): Systems Biology Insights for Hepatoprotecti

  2026-07-06

  Explore how Bifendate (DDB) advances hepatoprotection research through a systems biology lens. This article delivers in-depth analysis of its mechanistic roles in autophagy inhibition, lipid regulation, and CYP3A4 modulation—bridging practical protocols with emerging translational science.

• Cyanidin Chloride: Anti-Inflammatory and Barrier Effects in

  2026-07-05

  A recent study demonstrates that cyanin chloride, a glycosylated anthocyanin related to cyanidin chloride, effectively reduces inflammation and restores skin barrier function in a human cell-based psoriasis model. These findings highlight the compound’s mechanistic potential for oxidative stress and inflammatory skin disease research.

• Paeoniflorigenone Targets HIF1A to Inhibit Cholangiocarcinom

  2026-07-04

  This study identifies paeoniflorigenone (PFG) as a potent inhibitor of cholangiocarcinoma proliferation, acting via the HIF1A signaling pathway and enhancing cisplatin sensitivity. The findings highlight a novel therapeutic strategy and provide mechanistic insights for future research on cell cycle-targeted interventions.

• DNA-PK and ATM Antagonism Shapes Cytokine Responses to DNA S

  2026-07-03

  This study defines how DNA-PK and ATM kinases generate distinct phosphorylation signatures that differentially regulate cytokine responses to DNA damage and herpesvirus infection. Its findings clarify the molecular interplay between DNA repair and innate immunity, providing a mechanistic foundation for translational research in oncology and infection.

• D-Lin-MC3-DMA: Mechanistic Advances in RNA Lipid Nanoparticl

  2026-07-03

  Explore the mechanistic breakthroughs of D-Lin-MC3-DMA as an ionizable cationic liposome for RNA therapeutics. This in-depth review uniquely dissects its molecular action, predictive optimization, and practical protocol guidance for advanced siRNA and mRNA delivery.

• Eicosapentaenoic Acid: Applied Workflows and Troubleshooting

  2026-07-02

  Eicosapentaenoic Acid (EPA) is transforming cardiovascular disease research with its dual lipid-lowering and anti-inflammatory actions. This guide provides protocol-driven insights, troubleshooting strategies, and advanced application frameworks to help researchers maximize the translational impact of EPA omega-3 fatty acid in experimental models.

• Bergeyella cardium Variant Triggers Unique Floatptosis in Ma

  2026-07-02

  This study identifies a novel form of cytoplasmic vacuolization-mediated cell death, termed 'floatptosis,' induced by a Bergeyella cardium variant in macrophages. The findings expand our understanding of host-pathogen interactions and present new mechanistic targets for modulating immune responses and infectious disease outcomes.

• Ceapin-A7: Selective ER Stress Blocker for Advanced Cell Ass

  2026-07-01

  Ceapin-A7 empowers researchers to dissect the ATF6α arm of the ER stress response with unparalleled selectivity, unlocking new strategies in cellular stress and inflammation studies. Its robust inhibition profile and compatibility with diverse cell models make it a gold-standard chemical probe for pathway-specific modulation.

16328 records 1/1089 page Next 12345 下5页 Last page